
ALN-CC5-004 EudraCT Termination Summary

Title of Trial: A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

EudraCT Number: 2017-001082-24

Date of Termination: 12-September-2018

Protocol Number: ALN-CC5-004

Rationale: The Sponsor terminated the study due to lack of enrollment. No patients were enrolled or dosed. Study was not terminated on the grounds of safety.